Research |

 Relevant Publications

 

1

 

The following research publications were supported by the Centre:

1. CHK1 inhibition synergizes with Gemcitabine initially by destabilizing the DNA replication apparatus
Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI.
Cancer Res. 2015 Sep 1; 75(17): 3583-95.
2. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.
Br J Cancer. 2014 Jul 15; 111(2): 318-25.
3. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.
Proc Natl Acad Sci USA. 2013 Dec 10; 110(50): 20212-7.
4. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.
Gut. 2013 Sep 25. doi: 10.1136/gutjnl-2013-3055593.
5. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.
PLoS One. 2013 Jun 28;8(6):e67330
6. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA.
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30.
7. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD.
Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, Connor SC.
Mol Biosyst. 2012 Oct 30;8(12):3125-33.
8. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.
Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI.
Br J Cancer. 2012 Nov 6;107(10):1692-701.
9. Progress in pancreatic cancer: moving beyond gemcitabine?
Basu B, Jodrell D.
Expert Rev Anticancer Ther. 2012 Aug;12(8):997-1000.
10. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Wessels LF, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ, Tuveson DA.
Nature. 2012 Apr 29;486(7402):266-70.
11. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Jacobetz MA, Chan DS, Neessee A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.
Gut. 2012 Mar 30 (Epub ahead of print)
12. nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Frese KK, Neesse A, Cook N, Bapiro T, Lolkema MP, Jodrell DI, Tuveson DA.
Cancer Discovery. 2012, In press.
13. Gamma Secretase inhibition promotes hypoxic necrosis in murine pancreatic ductal adenocarcinoma.
Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T,
Howat WT, Jodrell DI, Tuveson DA.
J Exp Med. 2012 Mar 12;209(3):437-44.
14. A novel method for quantification of gemcitabine and its metabolites 2’,2’-
difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS:
comparison with (19)F NMR spectroscopy.

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.
Cancer Chemother Pharmacol. 2011 Nov; 68(5): 1243-53.
15. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA.
Nature. 2011 Jul 6;475(7354):106-9.